{"id":"sarpogrelate","rwe":[{"pmid":"40876613","year":"2025","title":"Relationship between serotonin and vascular dysfunction and the impact of 5-HT(2A) receptor blockade by sarpogrelate on vascular function in diabetes mellitus.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"40506945","year":"2025","title":"Study Design and Rationale of a Randomized Trial Comparing Aspirin-Sarpogrelate Combination Therapy with Aspirin Monotherapy: Effects on Blood Viscosity and Microcirculation in Cardiovascular Patients.","finding":"","journal":"Diagnostics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40371325","year":"2025","title":"Huangkui capsules regulate tryptophan metabolism to improve diabetic nephropathy through the Keap1/Nrf2/HO-1 pathway.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"40332700","year":"2025","title":"Effect of Sarpogrelate on Cerebral Venous Sinus Thrombosis Model.","finding":"","journal":"Applied biochemistry and biotechnology","studyType":"Clinical Study"},{"pmid":"40215388","year":"2025","title":"Efficacy and safety of antiplatelet therapy for secondary prevention of small subcortical infarction: A systematic review and network meta-analysis.","finding":"","journal":"European stroke journal","studyType":"Clinical Study"}],"tags":[{"label":"sarpogrelate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"HTR2C","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"Active","category":"status"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Fibrinolytic Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":45.705,"date":"","count":22,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=46)"},{"llr":45.207,"date":"","count":19,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=45)"}],"commonSideEffects":[{"effect":"Interstitial lung disease","drugRate":"LLR 46","severity":"common"},{"effect":"Hepatic function abnormal","drugRate":"LLR 45","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"anplag","offLabel":[],"synonyms":["anplag","MCI-9042","sarpogrelate","sarpogrelate hydrochloride","sarpogrelate HCl"],"timeline":[],"aiSummary":"Anplag, also known as Sarpogrelate, is a small molecule serotonin 2a (5-HT2a) receptor antagonist. It has been studied in clinical trials for various conditions, including Diabetic Nephropathy, Hypertension, Peripheral Artery Disease, Coronary Artery Disease, and Chronic Kidney Disease.","approvals":[],"brandName":"Anplag","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"}],"modality":"Small Molecule","drugClass":"sarpogrelate","explanation":"Imagine your blood vessels are like roads in your body. When they constrict, it's like a traffic jam. By blocking the 5-hydroxytryptamine receptor 2A, Anplag helps to relax the blood vessels, allowing blood to flow more easily and reducing the risk of conditions like Raynaud's disease.","oneSentence":"Anplag works by blocking the 5-hydroxytryptamine receptor 2A, which helps to relax blood vessels and improve blood flow.","technicalDetail":"Anplag selectively antagonizes the 5-hydroxytryptamine receptor 2A, a G protein-coupled receptor involved in vasoconstriction and platelet aggregation, thereby exerting its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2423","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SARPOGRELATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SARPOGRELATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:38:35.278424","biosimilars":[],"competitors":[{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amisulpride","drugSlug":"amisulpride","fdaApproval":"2020-02-26","patentExpiry":"Mar 10, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxicillin","drugSlug":"amoxicillin","fdaApproval":"1974-12-09","patentExpiry":"May 7, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole lauroxil","drugSlug":"aripiprazole-lauroxil","fdaApproval":"2015-10-05","patentExpiry":"Sep 8, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"sarpogrelate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amisulpride","brandName":"amisulpride","genericName":"amisulpride","approvalYear":"2020","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"amoxicillin","brandName":"amoxicillin","genericName":"amoxicillin","approvalYear":"1974","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"aripiprazole-lauroxil","brandName":"aripiprazole lauroxil","genericName":"aripiprazole lauroxil","approvalYear":"2015","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05730621","phase":"PHASE4","title":"A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2023-01-11","conditions":["Sarpogrelate","Blood Viscosity","Peripheral Arterial Disease","Coronary Artery Disease"],"enrollment":68,"completionDate":"2024-02-28"},{"nctId":"NCT05083299","phase":"","title":"Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-01-28","conditions":["Chronic Occlusive Arterial Disease"],"enrollment":1003,"completionDate":"2022-01-20"},{"nctId":"NCT06424548","phase":"NA","title":"Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis.","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Seoul Hospital","startDate":"2024-05-16","conditions":["Stroke","Atherosclerosis"],"enrollment":100,"completionDate":"2028-12-31"},{"nctId":"NCT06046196","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-11-18","conditions":["Arterial Occlusive Diseases","Intermittent Claudication"],"enrollment":148,"completionDate":"2023-03-09"},{"nctId":"NCT01869881","phase":"PHASE4","title":"Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-02-01","conditions":["Diabetic Nephropathy"],"enrollment":151,"completionDate":"2015-01-28"},{"nctId":"NCT03509922","phase":"PHASE4","title":"A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-11","conditions":["Peripheral Artery Disease, PAD"],"enrollment":60,"completionDate":"2020-03-05"},{"nctId":"NCT03947489","phase":"PHASE1","title":"Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-03-04","conditions":["Healthy"],"enrollment":38,"completionDate":"2019-05-06"},{"nctId":"NCT03947528","phase":"PHASE1","title":"Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-03-04","conditions":["Healthy"],"enrollment":38,"completionDate":"2019-05-13"},{"nctId":"NCT03573622","phase":"PHASE1","title":"A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-05-31","conditions":["Healthy"],"enrollment":62,"completionDate":"2018-10-12"},{"nctId":"NCT03574285","phase":"PHASE1","title":"A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-05-31","conditions":["Healthy"],"enrollment":48,"completionDate":"2018-10-12"},{"nctId":"NCT01674686","phase":"PHASE4","title":"The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-08-01","conditions":["Variant Angina"],"enrollment":200,"completionDate":"2018-12-31"},{"nctId":"NCT02959606","phase":"PHASE4","title":"SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-12","conditions":["Peripheral Arterial Disease"],"enrollment":272,"completionDate":"2019-01"},{"nctId":"NCT02393612","phase":"PHASE3","title":"Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2012-10","conditions":["Peripheral Arterial Disease"],"enrollment":151,"completionDate":"2014-04"},{"nctId":"NCT02607436","phase":"PHASE4","title":"Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-07","conditions":["Coronary Artery Disease"],"enrollment":40,"completionDate":"2016-04"},{"nctId":"NCT00147303","phase":"PHASE3","title":"Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-04","conditions":["Cerebral Infarction"],"enrollment":46,"completionDate":"2005-01"},{"nctId":"NCT02097511","phase":"PHASE1","title":"Sarpogrelate Drug Interaction","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2013-12","conditions":["Hypertension","Peripheral Artery Disease"],"enrollment":9,"completionDate":"2014-12"},{"nctId":"NCT02294643","phase":"PHASE3","title":"Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-04","conditions":["Coronary Artery Disease","Diabetes Mellitus","Renal Insufficiency, Chronic"],"enrollment":220,"completionDate":"2014-03"},{"nctId":"NCT01841086","phase":"PHASE1","title":"Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation","status":"COMPLETED","sponsor":"Korea United Pharm. Inc.","startDate":"2011-09","conditions":["Healthy"],"enrollment":50,"completionDate":"2011-12"},{"nctId":"NCT01548274","phase":"NA","title":"Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2010-10","conditions":["Atherosclerosis"],"enrollment":20,"completionDate":"2012-10"},{"nctId":"NCT01429688","phase":"PHASE1","title":"Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-07","conditions":["Healthy"],"enrollment":36,"completionDate":"2011-08"},{"nctId":"NCT01421563","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-02","conditions":["Healthy"],"enrollment":36,"completionDate":"2011-02"},{"nctId":"NCT01421576","phase":"PHASE1","title":"Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-07","conditions":["Healthy"],"enrollment":24,"completionDate":"2011-07"},{"nctId":"NCT01165567","phase":"PHASE4","title":"The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Seoul National University Boramae Hospital","startDate":"2009-12","conditions":["Chronic Kidney Disease"],"enrollment":212,"completionDate":"2010-12"},{"nctId":"NCT00129805","phase":"PHASE3","title":"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2001-01","conditions":["Cerebral Infarction"],"enrollment":1510,"completionDate":"2004-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"19P708E787","CHEBI":"CHEBI:135697","INN_ID":"6611","UMLSCUI":"C0286592","ChEMBL_ID":"CHEMBL541829","KEGG_DRUG":"D01624","DRUGBANK_ID":"DB12163","PUBCHEM_CID":"5160","IUPHAR_LIGAND_ID":"210","SECONDARY_CAS_RN":"135159-51-2","MESH_SUPPLEMENTAL_RECORD_UI":"C064294"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct 15","pmid":"40876613","title":"Relationship between serotonin and vascular dysfunction and the impact of 5-HT(2A) receptor blockade by sarpogrelate on vascular function in diabetes mellitus.","journal":"European journal of pharmacology"},{"date":"2025 May 29","pmid":"40506945","title":"Study Design and Rationale of a Randomized Trial Comparing Aspirin-Sarpogrelate Combination Therapy with Aspirin Monotherapy: Effects on Blood Viscosity and Microcirculation in Cardiovascular Patients.","journal":"Diagnostics (Basel, Switzerland)"},{"date":"2025","pmid":"40371325","title":"Huangkui capsules regulate tryptophan metabolism to improve diabetic nephropathy through the Keap1/Nrf2/HO-1 pathway.","journal":"Frontiers in pharmacology"},{"date":"2025 Jul","pmid":"40332700","title":"Effect of Sarpogrelate on Cerebral Venous Sinus Thrombosis Model.","journal":"Applied biochemistry and biotechnology"},{"date":"2025 Dec","pmid":"40215388","title":"Efficacy and safety of antiplatelet therapy for secondary prevention of small subcortical infarction: A systematic review and network meta-analysis.","journal":"European stroke journal"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}